Apptillion.

Public-company intelligence, source by source

NWBO Intelligence Monitor for $NWBO Investors and Enthusiasts

A scheduled, evidence-labeled briefing on Northwest Biotherapeutics, DCVax, regulators, trials, litigation, manufacturing, and meaningful investor discussion.

Primary sources firstRumors stay labeledConfirm before delivery
Enhanced loginCreate Enhanced account

Join the distribution

Choose how closely you want to follow NWBO.

Free keeps you current on the core record. Enhanced is built for readers who want faster discovery across the public X conversation without sacrificing verification.

Weekday editions are scheduled for 8:00 AM and 6:00 PM Eastern; weekend editions for 10:00 AM Eastern.

Choose your coverage

Enhanced rollout

Paid X access is moving through verification.

The Free Monitor remains account-free on its existing schedule. The separate $7/month Enhanced Monitor adds official X discovery and lets subscribers choose the fixed first, second, and weekend Eastern delivery windows after its production safety gates are complete.

X remains discovery evidence. Material claims still require primary or reputable non-X corroboration before they appear as confirmed or credibly reported.

Paid X cost controlOne cached collector is shared across all Enhanced subscribers
Expected month
$4–$6
Monthly hard cap
$10
Duplicate collection
Blocked

Current status: Accounts, billing, paid research, and delivery are implemented behind independent safety controls.

The interest poll remains open through August 27, 2026 at 12:00 noon ET. Public enrollment still waits for the production verification gates.

No account or payment is created before public enrollment opens.

Vote from your subscriber email

Use one of the two choices in the survey email. One click records your answer; no sign-in or typing is required.

Public archive

Previous day’s Free edition

NWBO Monitor - Edition September 1, 2026 - Since August 31, 6:00 PM ET - No New Confirmed Developments

No additional confirmed or credibly reported development appeared after the 8:00 AM edition. This cumulative evening edition recaps the two previously reported Canaccord docket entries and retains nine claim-centered community signals, including three distinct theories first surfaced after the morning edition. None of the new community theories was confirmed by a product-specific regulator, company filing, court order, trial result, or counterparty disclosure.

Covered August 31, 2026 at 6:00 PM EDT through September 1, 2026 at 6:00 PM EDT

This monitor organizes public information and authorized read-only community sources. It is not affiliated with Northwest Biotherapeutics and is not investment or medical advice.